Ocular Therapeutix (OCUL) Earnings: Q3 2026 Results and Next Report Date

The quarter ended September 30, 2026 and Ocular Therapeutix published the results on November 9, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison.

• All of Ocular Therapeutix's Q3 2026 revenue is DEXTENZA product revenue. Its lead candidate, AXPAXLI, is not approved, and the NDA for wet AMD is planned for 4Q 2026.

Source: Ocular Therapeutix Q3 2026 results, November 9, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP total revenue and net loss per share, each as first reported. Q4 2025 figures are from the Q4 2025 release.

Ocular Therapeutix's next report is expected around February 4, 2027, a date estimated from its reporting history that the company has not yet confirmed. This page will show Q3 2026 until those results are out and have been checked against the release.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 9, 2026

Ocular Therapeutix has one marketed product, DEXTENZA, a dexamethasone intracanalicular insert for post-surgical ocular inflammation and pain. Product revenue, net was $12.9 million in Q3 2026, down 11.0% from $14.5 million, and all of it came from DEXTENZA. (Ocular Therapeutix Q3 2026 release, Nov 9, 2026; Ocular Therapeutix Form 10-Q, Q3 2026, Nov 9, 2026; Ocular Therapeutix Form 10-K, 2025, Feb 5, 2026)

Ocular Therapeutix said unit growth was offset by larger gross-to-net adjustments, including more off-invoice discounts after a price increase in the second quarter of 2025. Gross-to-net provisions were 57.7% of gross DEXTENZA sales in Q3 2026, against 52.5% a year earlier. In-Market Sales, its demand measure, were about 49,000 units, about 1,000 fewer than in Q2 2026. (Ocular Therapeutix Form 10-Q, Q3 2026, Nov 9, 2026)

DEXTENZA is sold mainly to specialty distributors, who resell it to ambulatory surgery centers, hospital outpatient departments and physicians' offices, plus some direct sales. Three specialty distributors accounted for 48%, 24% and 8% of Q3 2026 total revenue. (Ocular Therapeutix Form 10-Q, Q3 2026, Nov 9, 2026)

For the rest of 2026 and beyond, Ocular Therapeutix expects unit volume to grow at an incremental rate compared with earlier 2026 quarters, with gross-to-net provisions stabilizing. Nine-month product revenue was $37.1 million, down 3.9%. (Ocular Therapeutix Form 10-Q, Q3 2026, Nov 9, 2026)

Ocular Therapeutix reports GAAP results only. Its net loss widened to $94.8 million, or $0.42 per share, from $69.4 million, or $0.38 per share. Research and development expense rose to $74.8 million from $52.4 million as enrollment accelerated in the HELIOS-3 diabetic retinopathy study and the SOL-X extension study. Selling and marketing rose to $15.7 million from $13.1 million on pre-commercial work for a potential AXPAXLI launch. (Ocular Therapeutix Q3 2026 release, Nov 9, 2026)

Weighted-average shares were 225,515,234, against 183,919,808 a year earlier. In October 2025 Ocular Therapeutix sold 37,909,018 shares in an underwritten offering for $445.6 million of net proceeds. The weighted count includes pre-funded warrants, of which 5,818,592 remained outstanding at September 30, 2026. Outstanding shares were about 220.0 million on November 6, 2026. (Ocular Therapeutix Q3 2026 release, Nov 9, 2026; Ocular Therapeutix Form 10-Q, Q3 2026, Nov 9, 2026)

Below the operating line, interest income was $5.0 million and interest expense $2.8 million on the $82.5 million Barings credit facility, and a $912 thousand gain on the fair value of derivative liabilities reduced the loss. (Ocular Therapeutix Q3 2026 release, Nov 9, 2026; Ocular Therapeutix Form 10-Q, Q3 2026, Nov 9, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Ocular Therapeutix gives no revenue or EPS guidance in its release. It says its $530.6 million of cash and cash equivalents at September 30, 2026 should fund planned operating expenses, debt service and capital spending into 2028, a projection that excludes the full cost of scaling manufacturing and the commercial team if AXPAXLI is approved. (Ocular Therapeutix Q3 2026 release, Nov 9, 2026)

The release puts the AXPAXLI NDA submission for wet AMD in 4Q 2026 under the 505(b)(2) pathway, after an interim SOL-R Week 52 safety analysis in the same quarter. SOL-R topline results are expected in 1Q 2028, with the primary endpoint moved to Week 40 from Week 56. (Ocular Therapeutix Q3 2026 release, Nov 9, 2026)

A consensus figure is the average of the models published by the analysts who cover Ocular Therapeutix, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Ocular Therapeutix's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning OCUL is on is OCUL a buy or a sell?, what analysts expect next is on the OCUL forecast, and what the company does is on the Ocular Therapeutix (OCUL) stock page.

Every number on this page can be traced to a document Ocular Therapeutix published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.